** Shares of Nvidia-backed AI drug developer Recursion Pharmaceuticals RXRX.O fall 13% to $6.67 premarket
** The company posts Q4 revenue of $4.5 million, missing analysts' estimate of $19 million, according to data compiled by LSEG
** Reports Q4 net loss of 53 cents per share versus a loss estimate of 43 cents per share
** Recursion wants to be the Amazon Prime of pharma by adopting a subscription model for selling its pipeline of medicines, Bloomberg reports
** The company files for stock offering of up to $500 million - filing
** It has ~390 mln outstanding shares, with a market capitalization of $3 bln, according to data compiled by LSEG
** RXRX has fallen ~51% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。